Many FDA-approved cancer drugs inhibit signaling proteins either directly recruited to IGF1R or downstream of the recruited proteins; thus, as different binding partners are more highly recruited in different cellular backgrounds, the most effective molecularly targeted drugs would likewise be cell type- or tumor-specific. The gene discussed is IGF1R; the disease is cancer.